标题
Harnessing the Power of the Immune System to Target Cancer
作者
关键词
-
出版物
Annual Review of Medicine
Volume 64, Issue 1, Pages 71-90
出版商
Annual Reviews
发表日期
2012-10-24
DOI
10.1146/annurev-med-112311-083918
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant
- (2014) S. Adams et al. JOURNAL OF IMMUNOLOGY
- Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma
- (2012) Richard Wu et al. CANCER JOURNAL
- BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency
- (2012) D. S. Hong et al. CLINICAL CANCER RESEARCH
- Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
- (2012) J. S. Khalili et al. CLINICAL CANCER RESEARCH
- Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans
- (2012) E. Corse et al. JOURNAL OF IMMUNOLOGY
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
- (2012) Hirokazu Matsushita et al. NATURE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
- (2011) Y. H. Kim et al. BLOOD
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma
- (2011) Stephen J. Schuster et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma
- (2011) Sofie Wilgenhof et al. JOURNAL OF IMMUNOTHERAPY
- Antitumor Activity Mediated by CpG
- (2011) Yanyan Lou et al. JOURNAL OF IMMUNOTHERAPY
- A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast Cancer
- (2011) Gary K. Koski et al. JOURNAL OF IMMUNOTHERAPY
- Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes
- (2011) Qunrui Ye et al. Journal of Translational Medicine
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
- (2011) Douglas J. Schwartzentruber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation
- (2011) Kajsa Wing et al. TRENDS IN IMMUNOLOGY
- Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients
- (2010) Qing Yi et al. BRITISH JOURNAL OF HAEMATOLOGY
- A High Molecular Weight Melanoma-Associated Antigen-Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
- (2010) W. R. Burns et al. CANCER RESEARCH
- Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naive Prostate Cancer Patients
- (2010) J. Karbach et al. CLINICAL CANCER RESEARCH
- Anti-GD3 Chimeric sFv-CD28/T-Cell Receptor Designer T Cells for Treatment of Metastatic Melanoma and Other Neuroectodermal Tumors
- (2010) A. S. Y. Lo et al. CLINICAL CANCER RESEARCH
- A Randomized Trial of Ex vivo CD40L Activation of a Dendritic Cell Vaccine in Colorectal Cancer Patients: Tumor-Specific Immune Responses Are Associated with Improved Survival
- (2010) R. J. Barth et al. CLINICAL CANCER RESEARCH
- CD8+ Enriched "Young" Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
- (2010) M. E. Dudley et al. CLINICAL CANCER RESEARCH
- Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy
- (2010) Robert M. Prins et al. CLINICAL CANCER RESEARCH
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
- (2010) B. C. Carthon et al. CLINICAL CANCER RESEARCH
- Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
- (2010) M. J. Besser et al. CLINICAL CANCER RESEARCH
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
- (2010) Joshua D. Brody et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of Adaptive Immunity by the Innate Immune System
- (2010) A. Iwasaki et al. SCIENCE
- Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy
- (2010) Margaret K. Callahan et al. SEMINARS IN ONCOLOGY
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
- (2009) L. A. Johnson et al. BLOOD
- Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
- (2009) K. S. Peggs et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells
- (2009) E. Yvon et al. CLINICAL CANCER RESEARCH
- Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study
- (2009) John A. Thompson et al. Clinical Genitourinary Cancer
- Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
- (2009) Ranjana Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Minimally Cultured or Selected Autologous Tumor-infiltrating Lymphocytes After a Lympho-depleting Chemotherapy Regimen in Metastatic Melanoma Patients
- (2009) Michal J. Besser et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- CTLA-4 suppresses the pathogenicity of self antigen–specific T cells by cell-intrinsic and cell-extrinsic mechanisms
- (2009) Wataru Ise et al. NATURE IMMUNOLOGY
- Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
- (2009) Gemma G. Kenter et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma
- (2008) R. Dummer et al. CLINICAL CANCER RESEARCH
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
- (2008) Mark E. Dudley et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma
- (2008) Maja A. Hofmann et al. JOURNAL OF IMMUNOTHERAPY
- A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas
- (2008) Nicholas Butowski et al. JOURNAL OF NEURO-ONCOLOGY
- A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)
- (2008) Nicholas Butowski et al. JOURNAL OF NEURO-ONCOLOGY
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
- (2008) Naomi N. Hunder et al. NEW ENGLAND JOURNAL OF MEDICINE
- CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- (2008) C. I. Liakou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search